BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23288641)

  • 1. Targeted therapy of multiple myeloma.
    Dolloff NG; Talamo G
    Adv Exp Med Biol; 2013; 779():197-221. PubMed ID: 23288641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.
    Chesi M; Kuehl WM; Bergsagel PL
    Ann Oncol; 2000; 11 Suppl 1():131-5. PubMed ID: 10707795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma.
    Laubach J; Richardson P; Anderson K
    Annu Rev Med; 2011; 62():249-64. PubMed ID: 21090965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinguishing primary and secondary translocations in multiple myeloma.
    Gabrea A; Leif Bergsagel P; Michael Kuehl W
    DNA Repair (Amst); 2006 Sep; 5(9-10):1225-33. PubMed ID: 16829212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.
    Bazzi M; Badros A
    Cancer Biol Ther; 2010 Nov; 10(9):830-8. PubMed ID: 21045554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.
    Bergsagel PL; Kuehl WM
    Immunol Rev; 2003 Aug; 194():96-104. PubMed ID: 12846810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Vallet S; Witzens-Harig M; Jaeger D; Podar K
    Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging strategies for targeting cell adhesion in multiple myeloma.
    Nair RR; Gebhard AW; Emmons MF; Hazlehurst LA
    Adv Pharmacol; 2012; 65():143-89. PubMed ID: 22959026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pomalidomide for multiple myeloma].
    Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
    Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetics and molecular cytogenetics in multiple myeloma.
    Liebisch P; Döhner H
    Eur J Cancer; 2006 Jul; 42(11):1520-9. PubMed ID: 16781866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome translocations in multiple myeloma.
    Bergsagel PL; Kuehl WM
    Oncogene; 2001 Sep; 20(40):5611-22. PubMed ID: 11607813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.